| Literature DB >> 32586027 |
Chia-Ming Yeh1,2,3, Chiao-Wen Lin4,5, Hsueh-Ju Lu6,7, Chun-Yi Chuang7,8, Chia-Hsuan Chou1, Shun-Fa Yang1,9, Mu-Kuan Chen1,2,3.
Abstract
Oral cancer is among the most common cancers worldwide and has become a major global health problem because of its relatively high morbidity and mortality rates. The sex-determining region on the Y-chromosome-related high-mobility-group box (SOX) transcription factor 11 (SOX11) plays a key role in human development and differentiation and is frequently increased in various human cancers. However, the clinical significance of SOX11 polymorphisms in oral cancer and their association with oral cancer risk are unclear. In this study, we included 1196 patients with oral cancer and 1200 controls. Real-time polymerase chain reaction was applied to analyze three SOX11 single-nucleotide polymorphisms (rs77996007, rs66465560, and rs68114586). Our results shown that SOX11 polymorphisms carriers with betel quid chewing were found to have an 8.38- to 9.23-fold risk to have oral cancer compared to SOX11 wild-type carriers without betel quid chewing. Furthermore, oral cancer patients who carried SOX11 rs77996007 "TC + CC" variants were significantly associated with large tumor size (AOR, 1.324; 95% CI, 1.047-1.674; p= 0.019). Moreover, a database analysis using the Cancer Genome Atlas suggested that SOX11 mRNA expression was high during the tumor development process. In conclusion, our results suggest that SOX11 rs77996007 is involved in oral cancer progression and clinical characteristics.Entities:
Keywords: SOX11; metastasis; oral squamous cell carcinoma; single nucleotide polymorphisms
Mesh:
Substances:
Year: 2020 PMID: 32586027 PMCID: PMC7352504 DOI: 10.3390/ijms21124468
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
The distributions of demographical characteristics in 1200 controls and 1196 male patients with oral cancer.
| Variable | Controls ( | Patients ( | |
|---|---|---|---|
| Age (yrs) | |||
| ≦55 | 610 (50.8%) | 609 (50.9%) | |
| >55 | 590 (49.2%) | 587 (49.1%) | |
| Betel quid chewing | |||
| No | 1001 (83.4%) | 321 (26.8%) | |
| Yes | 199 (16.6%) | 875 (73.2%) | |
| Cigarette smoking | |||
| No | 564 (47.0%) | 192 (16.0%) | |
| Yes | 636 (53.0%) | 1004 (84.0%) | |
| Alcohol drinking | |||
| No | 963 (80.2%) | 648 (54.2%) | |
| Yes | 237 (19.8%) | 548 (45.8%) | |
| Stage | |||
| I + II | 565 (47.2%) | ||
| III + IV | 631 (52.8%) | ||
| Tumor T status | |||
| T1 + T2 | 599 (50.1%) | ||
| T3 + T4 | 597 (49.9%) | ||
| Lymph node status | |||
| N0 | 796 (66.6%) | ||
| N1 + N2 + N3 | 400 (33.4%) | ||
| Metastasis | |||
| M0 | 1186 (99.2%) | ||
| M1 | 10 (0.8%) | ||
| Cell differentiation | |||
| Well differentiated | 170 (14.2%) | ||
| Moderately or poorly differentiated | 1026 (85.8%) |
Fisher’s exact test was used between healthy controls and patients with oral cancer. * p-value < 0.05 was considered statistically significant.
The adjusted odds ratio (AOR) and 95% confidence interval (CI) of oral cancer associated with SOX11 genotypic frequencies.
| Variable | Controls | Patients | OR (95% CI) | AOR (95% CI) b |
|---|---|---|---|---|
|
| ||||
| TT | 514 (42.8%) | 470 (39.3%) | 1.000 (reference) | 1.000 (reference) |
| TC | 526 (43.8%) | 586 (49.0%) | 1.218 (1.026–1.446) a | 1.076 (0.871–1.328) |
| CC | 160 (13.4%) | 140 (11.7%) | 0.957 (0.739–1.240) | 0.923 (0.670–1.271) |
| TC + CC | 686 (57.2%) | 726 (60.7%) | 1.157 (0.983–1.362) | 1.042 (0.853–1.272) |
|
| ||||
| TT | 911 (75.9%) | 921 (77.0%) | 1.000 (reference) | 1.000 (reference) |
| TC | 271 (22.6%) | 265 (22.2%) | 0.967 (0.798–1.173) | 0.965 (0.762–1.223) |
| CC | 18 (1.5%) | 10 (0.8%) | 0.550 (0.252–1.197) | 0.424 (0.163–1.099) |
| TC + CC | 289 (24.1%) | 275 (23.0%) | 0.941 (0.779–1.137) | 0.929 (0.736–1.171) |
|
| ||||
| Ins/Ins | 912 (76.0%) | 921 (77.0%) | 1.000 (reference) | 1.000 (reference) |
| Ins/Del | 269 (22.4%) | 264 (22.1%) | 0.972 (0.801–1.179) | 0.978 (0.772–1.240) |
| Del/Del | 19 (1.6%) | 11 (0.9%) | 0.573 (0.271–1.211) | 0.435 (0.174–1.090) |
| Ins/Del or Del/Del | 288 (24.0%) | 275 (23.0%) | 0.946 (0.783–1.142) | 0.939 (0.745–1.184) |
The odds ratio (OR) with their 95% confidence intervals were estimated by logistic regression models. a p = 0.024. b The adjusted odds ratio (AOR) with their 95% confidence intervals were estimated by multiple logistic regression models after controlling for age, betel quid chewing, cigarette smoking, and alcohol drinking.
The odds ratio (OR) and adjusted odds ratio (AOR) and 95% confidence interval (CI) of oral cancer associated with SOX11 genotypic frequencies.
| Variable | Controls | Patients | OR (95% CI) | AOR (95% CI) | ||
|---|---|---|---|---|---|---|
|
| ||||||
| ≦55 | 610 (50.8%) | 609 (50.9%) | 1.000 (reference) | 1.000 (reference) | ||
| >55 | 590 (49.2%) | 587 (49.1%) | 0.997 (0.849–1.170) | 1.283 (1.053–1.564) | ||
|
| ||||||
| No | 1001 (83.4%) | 321 (26.8%) | 1.000 (reference) | 1.000 (reference) | ||
| Yes | 199 (16.6%) | 875 (73.2%) | 13.711 (11.240–16.726) | 10.708 (8.539–13.428) | ||
|
| ||||||
| No | 564 (47.0%) | 192 (16.0%) | 1.000 (reference) | 1.000 (reference) | ||
| Yes | 636 (53.0%) | 1004 (84.0%) | 4.637 (3.829–5.616) | 1.398 (1.103–1.773) | ||
|
| ||||||
| No | 963 (80.2%) | 648 (54.2%) | 1.000 (reference) | 1.000 (reference) | ||
| Yes | 237 (19.8%) | 548 (45.8%) | 3.436 (2.864–4.122) | 1.499 (1.197–1.877) | ||
|
| ||||||
| TT | 514 (42.8%) | 470 (39.3%) | 1.000 (reference) | 1.000 (reference) | ||
| TC + CC | 686 (57.2%) | 726 (60.7%) | 1.157 (0.983–1.362) | 1.034 (0.844–1.268) | ||
|
| ||||||
| TT | 911 (75.9%) | 921 (77.0%) | 1.000 (reference) | 1.000 (reference) | ||
| TC + CC | 289 (24.1%) | 275 (23.0%) | 0.941 (0.779–1.137) | 0.572 (0.125–2.619) | ||
|
| ||||||
| Ins/Ins | 912 (76.0%) | 921 (77.0%) | 1.000 (reference) | 1.000 (reference) | ||
| Ins/Del or Del/Del | 288 (24.0%) | 275 (23.0%) | 0.946 (0.783–1.142) | 1.665 (0.362–7.650) |
The adjusted odds ratio (AOR) with their 95% confidence intervals were estimated by multiple logistic regression models after controlling for age, betel quid chewing, cigarette smoking, and alcohol drinking.
Associations of the combined effect of SOX11 gene polymorphisms and betel nut chewing with the susceptibility to oral cancer among 1640 smokers.
| Variable | Controls ( | Patients ( | OR (95% CI) | AOR (95% CI) |
|---|---|---|---|---|
|
| ||||
| TT genotype & non-betel nut chewing | 196 (30.8%) | 86 (8.6%) | 1.000 (reference) | 1.000 (reference) |
| TC or CC genotype or betel nut chewing | 330 (51.9%) | 406 (40.4%) | 2.804 (2.094–3.755) | 2.623 (1.949–3.530) |
| TC or CC genotype with betel nut chewing | 110 (17.3%) | 512 (51.0%) | 10.608 (7.652–14.705) | 9.225 (6.610–12.874) |
|
| ||||
| TT genotype & non-betel nut chewing | 336 (52.8%) | 138 (13.8%) | 1.000 (reference) | 1.000 (reference) |
| TC or CC genotype or betel nut chewing | 252 (39.6%) | 678 (67.5%) | 6.551 (5.126–8.372) | 5.872 (4.575–7.535) |
| TC or CC genotype with betel nut chewing | 48 (7.6%) | 188 (18.7%) | 9.536 (6.562–13.859) | 8.376 (5.735–12.234) |
|
| ||||
| Ins/Ins genotype & non-betel nut chewing | 338 (53.1%) | 138 (13.8%) | 1.000 (reference) | 1.000 (reference) |
| Ins/Del or Del/Del genotype or betel nut chewing | 251 (39.5%) | 677 (67.4%) | 6.606 (5.169–8.443) | 5.934 (4.625–7.613) |
| Ins/Del or Del/Del genotype with betel nut chewing | 47 (7.4%) | 189 (18.8%) | 9.849 (6.763–14.343) | 8.653 (5.913–12.664) |
The adjusted odds ratio (AOR) with their 95% confidence intervals were estimated by multiple logistic regression models after controlling for age and alcohol drinking.
The adjusted odds ratio (AOR) and 95% confidence intervals (CI) of clinical statuses associated with genotypic frequencies of SOX11 rs77996007 in male oral cancer patients (n = 1196).
| Variable | AOR (95% CI) | |||
|---|---|---|---|---|
|
| ||||
|
| Stage I + II | Stage III + IV | ||
| ( | ( | |||
| TT | 238 (42.1%) | 232 (36.8%) | 1.00 | |
| TC + CC | 327 (57.9%) | 399 (63.2%) | 1.252 (0.991–1.582) | |
|
| ||||
|
| ≦T2 | >Τ2 | ||
| ( | ( | |||
| TT | 255 (42.6%) | 215 (36.0%) | 1.00 | |
| TC + CC | 344 (57.4%) | 382 (64.0%) | 1.324 (1.047–1.674) | |
|
| ||||
|
| No | Yes | ||
| ( | ( | |||
| TT | 313 (39.3%) | 157 (39.3%) | 1.00 | |
| TC + CC | 483 (60.7%) | 243 (60.7%) | 1.000 (0.780–1.282) | |
|
| ||||
|
| M0 | M1 | ||
| ( | ( | |||
| TT | 468 (39.5%) | 2 (20.0%) | 1.00 | |
| TC + CC | 718 (60.5%) | 8 (80.0%) | 2.645 (0.555–12.597) | |
|
| ||||
|
| ≦Grade I ( | >Grade I ( | ||
| TT | 63 (37.1%) | 407 (39.7%) | 1.00 | |
| TC + CC | 107 (62.9%) | 619 (60.3%) | 0.889 (0.634–1.246) | |
Cell differentiate grade: grade I: well differentiated; grade II: moderately differentiated; grade III: poorly differentiated. The adjusted odds ratio (AOR) with their 95% confidence intervals were estimated by multiple logistic regression models after controlling for age, betel quid chewing, cigarette smoking, and alcohol drinking. * p-value < 0.05 as statistically significant.
Figure 1Association of SOX11 mRNA level and clinical status from the TCGA database. (A) The SOX11 mRNA level of HNSCC tissues were compared to normal tissues. (B) The SOX11 mRNA level were compared according to adjacent normal tissues and HNSCC tissues. (C) The SOX11 mRNA levels were compared according to tumor stage. (D) The SOX11 mRNA levels were compared according to tumor clinical T stage. (E) The SOX11 mRNA levels were compared according to clinical n stage. (F) Boxplots of RNA-Seq for SOX11 mRNA demonstrating significantly altered expression in diploid versus deletion and gain cancers.